medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2020, Number 1

<< Back

VacciMonitor 2020; 29 (1)

Cuban Meningococcal Vaccine VA-MENGOC-BC®: 30 Years of Use and Future Potential

Sierra-González VG

Language: Portugués
References: 71
Page: 32-43
PDF size: 543.90 Kb.


ABSTRACT

Every year, meningococcal infection by Neisseria meningitidis causes over 500,000 cases and 85,000 deaths in the world, with 20% of survivors suffering sequelae. In Cuba its incidence in 1980 reached 5.9 cases per 100,000 population; about 80% of cases were serogroup B, prompting health authorities to declare meningococcal disease the country’s main public health problem. Several provinces reported over 120 cases per 100,000 children aged <1 year, overwhelmingly serogroup B. At that time, no vaccines existed with proven efficacy against N. meningitidis serogroup B, nor was there a vaccine candidate that could be successful in the short term. By 1989, researchers in Havana had developed a Cuban meningococcal B and C vaccine, VA-MENGOC-BC®, the world’s first against serogroup B meningococcal disease. Its efficacy of 83% was demonstrated in a prospective, randomized, double-blind, placebo-controlled field study. Vaccine production used vesicle or proteoliposome technology for the first time. The same year, the World Intellectual Property Organization awarded its gold medal to the main authors of the VA-MENGOC-BC® patent. The vaccine was used in a mass vaccination campaign and later included in Cuba’s National Immunization Program, with a cumulative impact on incidence of serogroup B meningococcal disease greater than 95% (93%-98%). Mass, systematic vaccination shifted the spectrum of meningococcal strains in healthy asymptomatic carriers and strains circulating among population groups toward nonvirulent phenotypes. The disease ceased to be a public health problem in the country. VA-MENGOC-BC® is the most widely applied vaccine against serogroup B meningococcal disease in the world. Over 60 million doses have been administered in Latin America. In several countries where it has been applied, in which strains other than the vaccine-targeted strains circulate, VA-MENGOC-BC® has demonstrated effectiveness against all (55%-98% in children aged ≥4 years and 73%-100% in children aged >4 years). The vaccine and its proteoliposome technology have had an impact and continue to have potential, not only for meningococcal disease, but also for development of other vaccines and adjuvants.


REFERENCES

  1. Vieusseux M. Memoire sur la maladie qui a régné à Genève au printemps de 1805. J Med Clin Pharm. 1805;11:163–82.

  2. Weichselbaum A. Ueber die aetiologie der akuten meningitis cerebro-spinal. Fortschr Med. 1887;5:573–83, 620–63.

  3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63.

  4. Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321. doi: 10.3389/fped.2018.00321

  5. Lukši I, Mulic R, Falconer R, Orban M, Sidhu S, Rudan I. Estimating global and regional morbidity from acute bacterial meningitis in children. Croat Med J. 2013;54(6):510–8.

  6. Edmond K, Clark A, Korczak VS, Sanderson C, Griffitths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:317–28.

  7. Caugant DA, Maiden MC. Meningococcal carriage and disease–population biology and evolution. Vaccine. 2009;27(Suppl 2):B64–70.

  8. Valcárcel M, Rodríguez R, Terry H. La Enfermedad Meningocócica en Cuba: Cronología de una Epidemia. La Habana: Editorial de Ciencias Médicas; 1991.

  9. Zollinger WD, Mandrell RE, Altieri P, Berman S, Lowenthal J, Artenstein MS. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis. 1978;137:728–39.

  10. Helting TB, Guthöhrlein G, Blackkolb F, Ronneberger H. Serotype determinant protein of Neisseria meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells. Acta Pathol Microbiol Scand C. 1981;89(2):69–78.

  11. Frasch CE, Peppler MS. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun. 1982;37(1):271–80.

  12. Frøholm LO, Berdal BP, Bøvre K, Gaustad P, Harboe A, Holten E, et al. Meningococcal group B vaccine trial in Norway. Preliminary report of results available November 1983. NIPH Ann. 1983;6(2):133–8.

  13. Campa C, Sierra VG, Gutiérrez MM, Bisset G, García L, Puentes G, et al. Método para la obtención de una vacuna de amplio espectro protector contra Neisseria meninigitidis del serogrupo B y la vacuna resultante. Patente Cubana CU 21888 A1. 1989 Enero 6.

  14. Campa C, Sierra VG, Gutiérrez MM, Bisset G, García L, Puentes G, et al. Method for obtaining a vaccine with wide protective range against group B Neisseria meningitidis, the resulting vaccine, gammaglobulin and transfer factor. European Patent EP0301992 B1. 1995 Mayo 24.

  15. Masforrol Y, Gil J, García D, Noda J, Ramos Y, Betancourt L, et al. A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV based vaccine against N. meningitidis serogroup B and C. Hum Vaccin Immunother. 2017;13:2548–60.

  16. Sierra GV, Campa HC, Varcacel NM, García IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207.

  17. Tamargo B, Ramírez W, Márquez Y, Cedré B, Fresno M, Sierra G. New proteoliposomic formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potencial as well as Th-1 adjuvant capacity. BMC Immunology. 2013;14(Suppl 1):S12. Disponible en: http://www.biomedcentral.com/1471-2172/14/S1/S12 (Consultado en línea: 8 de enero de 2019)

  18. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED). VA-MENGOC-BC®. Vacuna antimeningocócica BC. La Habana: CECMED; 1987. Disponible en: http://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_va_mengoc_bc_2016_formato_cecmed_rev_rold_20161025.pdf. (Consultado en línea: 2 de mayo de 2019)

  19. Tamargo Santos B, Fleitas Pérez C, Infante Bourzac JF, Márquez Nápoles Y, Ramírez González W, Bourg V, et al. Remote induction of cellular immune response in mice by anti-meningococcal nanocochleates nanoproteoliposomes. Sci Total Environ. 2019;668:1055–63.

  20. Tamargo SB, Bungau S, Fleitas Pérez C, Márquez Nápoles Y, Infante Bourzac JF, Oliva Hernández R, et al. Immuno-toxicological evaluation of the adjuvant formulations for experimental antimeningococcal vaccines without aluminium hydroxide. Rev Chimie (Bucharest). 2019;70(4):1251–7.

  21. Pérez Rodríguez A, Dickinson F, Tamargo I, Sosa J, Quintana I, Ortiz P, et al. Resultados y experiencias de la vigilancia nacional de meningitis bacteriana en Cuba. Biotecnol Apl. 2003;20(2):118–22.

  22. Sotolongo Padrón F, Campa Huergo C, Casanueva Gil V, Fajardo Díaz EM, Cuevas Valdespino IE, González Gotera N. Cuban Meningococcal BC vaccine: experiences and contributions from 20 years of application. MEDICC Rev. 2007;9(1):16–22.

  23. Rodríguez M, Pérez A, Llanes R, Dickinson F, Cuevas, IE, Pérez K. Características epidemiológicas y microbiológicas en casos confirmados de enfermedad meningocócica en Cuba, 1998–2007. VacciMonitor. 2013;22(2):1–8.

  24. Martínez Motas I, Sierra González G, Núñez Gutiérrez N, Izquierdo Pérez L, Climent Ruíz Y, Mirabal Sosa M. Caracterización de cepas de Neisseria meningitidis aisladas de portadores em Cuba durante 20 años. Rev Cubana Med Trop. 2006;58(2):124–33.

  25. Climent Y, Yero D, Martínez I, Martín A, Jolley KA, Sotolongo F, et al. Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba. J Clin Microbiol. 2010;48:802–10.

  26. Law DK, Lorange M, Ringuette L, Dion R, Giguère M, Henderson AM, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol. 2006;44:2743–9.

  27. Pérez Rodríguez A, Dickinson Meneses F, Rodríguez Ortega M. Efectividad de la vacuna antimeningocócica VA-MENGOC-BC® en el primer año de vida, Cuba, 1997–2008. Rev Cubana Med Trop. 2011;63(2):155–60.

  28. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA. 1999;281:1520–7.

  29. Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis. 1998;177:683–91.

  30. Boutriau D, Poolman J, Borrow JR, Findlow J, Diez J, Puig-Barbera J, et al. Immunogenicity and safety of three doses of a bivalent meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol. 2007;14(1):65–73.

  31. Galguera Domínguez M, Sierra González G, Martínez Torres E, Campa Huergo C, Almeida González L, Le Riverend Morales L, et al. Utilización terapéutica de gamma globulina hiperinmune específica en la enfermedad meningocócica del niño. Rev Cubana Pediatr. 1991;63(1):55–62.

  32. Balboa GJA. Inmunoglobulina humana antimeningococcica: obtención, caracterización y capacidad protectora [tesis doctoral].La Habana: Instituto Finlay; 2006.

  33. Camero Santiesteban AA, Balboa González JA, Nerey Olivares MC, Malberty Agüero JA, Paradoa Pérez M, Joó Sánchez L, et al. Composición de inmunoglobulinas en la inmunoglobulina humana antimeningocócica. Rev Cubana Farm. 1998;32(3):151–6.

  34. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramón-Pardo P, et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med. 2017;14(7):e1002344. doi: 10.1371/journal.pmed.1002344

  35. Petousis-Harris H. Impact of meningococcal group B OMV vaccines, beyond their brief. Hum Vaccin Immunother. 2018;14:1058–63.

  36. Pérez O, del Campo J, Cuello M, González E, Nuñez N, Cabrera O, et al. Mucosal approaches in Neisseria vaccinology. VacciMonitor. 2009;18(2):55–7.

  37. Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390:1603–10.

  38. Paynter J, Goodyear-Smith F, Morgan J, Saxton P, Black S, Petousis-Harris H. Effectiveness of a Group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study. Vaccines (Basel). 2019;7(1). pii: E5. doi: 10.3390/vaccines7010005.

  39. Sierra González G, Tamargo Santos B. Adyuvantes inmunológicos para vacunas humanas; estado actual, tendencias mundiales y en Cuba. Anales Acad Cienc Cuba. 2011;1(2):1–32.

  40. Pérez Martín OG, Bracho Grando GR, Lastre González M, Sierra González VG, Campa Huergo C, Mora González N, et al. Method of obtaining cochlear structures, vaccine compositions, adjuvants and inter mediates thereof. World Intellectual Property Organization WO2004/047805 Al. 2004 Junio 10.

  41. Lastre González M, Pérez Martín O, Labrada Rosado A, Bidot Martínez I, Pérez Lastre J, Bracho Granada G, et al. Allergy vaccine composition, production method thereof and use of same in allergy treatment. World Intellectual Property Organization WO2003/094964. 2003 Nov 20.

  42. Pérez Martín O, González Aznar E, Romeu Álvarez B, Del Campo Alonso J, Acevedo Grogues R, Lastre González M, et al. Single-time vaccines. World Intellectual Property Organization WO2010/057447 A1. 2010 Mayo 27.

  43. Pérez Martín O, Pérez Cuello M, Cabrera Blanco O, Balboa González JA, Lastre González M, González Zayas V, et al. Adjuvanted tolerogens as a malaria vaccine. World Intellectual Property Organization WO2011/137876 A2. 2011 Nov 10.

  44. Fernández Molina LE, Sánchez Ramírez B, Suárez Pestana ER, De La Barrera Aira A, Mesa Pardillo C, De León Delgado J, et al. Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens. World Intellectual Property Organization WO2002/045746A2. 2002 Junio 13

  45. Estévez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 1999;18(1–2):190–7.

  46. Tamargo B, Rosario LA, Batista N, Arencibia DF, Fernández K, Villegas A, et al. Protección inducida por nanococleatos derivados de proteoliposomas de Leptospira interrogans serovar Canicola. VacciMonitor. 2012;21(1):3–9.

  47. Acevedo R, Callicó A, del Campo J, González E, Cedré B, González L, et al. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods 2009;49(4):309–15.

  48. Fernández S, Fajardo EM, Mandiarote A, Año G, Padrón MA, Acosta M, et al. A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models. BMC Immunol. 2013;14 Suppl 1:S8. doi: 10.1186/1471-2172-14-S1-S8.

  49. Pajón R, Chinea G, Marrero E, González D, Guillén G. Sequence analysis of the structural tbpA gene: protein topology and variable regions within neisserial receptors for transferrin iron acquisition. Microb Pathog. 1997;23(2):71–84.

  50. Delgado M, Yero D, Niebla O, Sardiñas G, González S, Caballero E, et al. Analysis of the genetic variability and immunological properties of the NlpB antigen, a novel protein identified in Neisseria meningitidis. Biotecnol Apl. 2009;26(1):85–7.

  51. Menéndez T, Santiago-Vispo NF, Cruz-Leal Y, Coizeau E, Garay H, Reyes O, et al. Identification and characterization of phage-displayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide. Int J Med Microbiol. 2011;301(1):16–25.

  52. Uli L, Castellanos Serra L, Betancourt L, Domínguez F, Barberá R, Sotolongo F, et al. Outer membrane vesicles of the VA-MENGOC-BC® vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2006;6:3389–99.

  53. Gil J, Betancourt LZ, Sardiñas G, Yero D, Niebla O, Delgado M, et al. Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens. Hum Vaccin. 2009;5(5):347–56.

  54. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED). CIMAvax®-EGF. (Conjugado químico de Factor de Crecimiento Epidérmico humano recombinante acoplado a la proteína recombinante rP64K). CIMAvax®-EGF. Vacuna terapéutica indicada para pacientes con cáncer de pulmón de células no pequeñas, en estadios avanzados (IIIb/IV). La Habana: CECMED; 2008. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_cima-vax_egf.pdf. (Consultado en línea: 15 de octubre de 2018).

  55. Silva R, Selman M, Guillén G, Herrera L, Fernández JR, Novoa LI, et al. Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations. European Patent EP0474313 A2. 1992 Marzo 11.

  56. Rodríguez Martínez GM, Viña Rodríguez L, Calvo González L, Cuevas Fiallo A, Chico Véliz E, Crombet Ramos T, et al. Production of an homogeneous vaccine preparation for cancer treatment. World Intellectual Property Organization WO 2009/003425 Al. 2009 Enero 8.

  57. Menéndez Medina T, Cruz Leal Y, Coizeau Rodríguez E, Guillén Nieto GE, Santiago Vispo NF, Cinza Estévez Z, et al. Mimotopes of capsular polysaccharides of Neisseria meningitidis and pharmaceutical formulations. World Intellectual Property Organization WO 2007/087758 A2. 2007 Agosto 9.

  58. Campa Huergo C, Sierra González G, Gutiérrez Vázquez MM, Bisset Jorrín G, García Imia LG, Puentes Rizo GC, et al. Method of producing of an anti-meningococ hyperimmune gamma globulin and gamma globulin produced by method. US Patent 5,747,653A. 1998 Mayo 5.

  59. Tania Crombet R, Rodríguez PC, Neninger Vinageras E, García Verdecia B, Lage Dávila A. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines 2015;14(10):1303–11.

  60. Zulueta A, Hermida L, Lazo L, Valdés I, Rodríguez R, López C, et al. The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun. 2003;308:619–26.

  61. Ochoa RF, Sierra G. Vacunas contra la enfermedad meningocócica. En: Ochoa RF, Menéndez J, editores. Prevención de la enfermedad meningocócica. 1ra ed. La Habana: Finlay Ediciones; 2010. p. 67–84.

  62. Rico O, Almeyda L. Impacto de la vacunación con VA-MENGOC-BC en los niños menores de seis años en algunas provincias de Cuba. Rev Soc Argentina Pediatr Filial Córdoba.1994;3(3):65–8.

  63. Costa EA, Martins H, Klein CH. Avaliação da proteção conferida pela vacina antimeningocócica BC no Estado de Santa Catarina, Brazil, 1990/92. Rev Saúde Pública. 1996;30(5):460–70.

  64. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol. 1995;24(5):1050–7.

  65. de Moraes JC, Perkins BA, Camargo MCC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340:1074–8.

  66. Costa EA, Amaral JC, Juárez E. Eficácia da vacina antimeningocócica (VA-MENGOC-BC®) nas condições de uso no Brasil, no período 1989/90. Inf Epidemiol SUS. 1994;3(2):35–9.

  67. Galeano LA, Echeverry ML. Efectividad de una vacuna antimeningocóccica en una cohorte de Itaguí, Colombia, 1995. Bol Epidemiol Antioquia. 1995;20(2):110–8.

  68. Pírez MC, Picón T, Galazka J, Rubio I, Montano A, Ferrari AM. Control de un brote epidémico de enfermedad meningocócica por Neisseria meningitidis serogrupo B. Rev Méd Urug. 2004;20(2):92–101.

  69. Ochoa-Azze RF. Cross-protection induced by VA-MENGOC-BC vaccine. Hum Vaccin Immunother. 2018;14:1064–8.

  70. Ochoa-Azze RF, García-Imía L, Vérez-Bencomo V. Effectiveness of a Serogroup B and C Meningococcal vaccine developed in Cuba. MEDICC Rev. 2018;20(3):22–9.

  71. Ochoa-Azze R, García-Imia L. Efectividad de la vacuna VA-MENGOC-BC® contra cepas heterólogas de meningococo B. VacciMonitor. 2016;25(2):43–8.




2020     |     www.medigraphic.com